apl. Prof. Dr. Stefan Krause

Medizinische Fakultät Department of Medicine 5 – Haematology and Oncology

Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia – long-term follow-up with focus on younger patients (2025) Rautenberg C, Middeke JM, Röllig C, Stelljes M, Gaidzik V, Kriege O, Verbeek M, et al. Journal article Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia (2025) Ruhnke L, Bill M, Zukunft S, Eckardt JN, Schäfer S, Stasik S, Hanoun M, et al. Journal article Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML. (2025) Unglaub JM, Schlenk RF, Middeke JM, Krause S, Kraus S, Einsele H, Kramer M, et al. Journal article The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AML (2025) Stasik S, Eckardt JN, Röllig C, Baldus CD, Platzbecker U, Serve H, Müller-Tidow C, et al. Journal article Metagenomic analysis of microbial cell-free DNA from plasma of patients with suspected infections: performance and therapeutic impact in clinical routine (2025) Esse J, Träger J, Steininger P, Bihlmaier K, Fürst J, Bardonicsek-Depnering Z, Naumann-Bartsch N, et al. Journal article VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML (2025) Kretschmer L, Ruhnke L, Schliemann C, Fransecky L, Steffen B, Kaufmann M, Burchert A, et al. Journal article Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis (2025) Ronnacker J, Muller PJ, Mikesch JH, Zukunft S, Weinbergerová B, Šrámek J, Valka J, et al. Journal article Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia (2024) Jaramillo S, Krisam J, Le Cornet L, Kratzmann M, Baumann L, Eissymont O, Crysandt M, et al. Journal article Single or Double Induction With 7 1 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia (2024) Röllig C, Steffen B, Schliemann C, Mikesch JH, Alakel N, Herbst R, Hänel M, et al. Journal article Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens. (2024) Baden D, Zukunft S, Hernandez G, Wolgast N, Steinhauser S, Pohlmann A, Schliemann C, et al. Journal article